David joined Akron Biotech in May 2020 to focus on global sales, marketing strategy, and to support Akron’s business development efforts by utilizing his deep expertise in the field of cell and gene therapy. Previously, he served on the Board Directors of Healios K.K. before he assumed the position of chief commercial officer of Healios NA, Inc., Healios’ subsidiary in the United States. In September 2019, he assumed the additional role of executive director of Manufacturing for Healios K.K. and was promoted to president of Healios NA. Prior to joining Healios, David held various roles at Cambrex Bioproducts. After Lonza’s acquisition of Cambrex, David became the head of Therapeutic Cell Solutions. By 2015, he was Lonza’s VP of Global Business Development, focusing on strategic agreements and alliances for the Emerging Technologies business unit, which includes cell and viral therapy. David also spent 14 years at The Upjohn Company in various sales and marketing roles, including leading the launch of the Parkinson’s therapeutic, Mirapex. David is a member of various government expert panels, company executive committees and advisory boards.